GRI Bio Inc (NASDAQ: GRI)’s stock price has plunge by 2.22relation to previous closing price of 0.52. Nevertheless, the company has seen a 3.58% surge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-28 that Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
Is It Worth Investing in GRI Bio Inc (NASDAQ: GRI) Right Now?
The 36-month beta value for GRI is at -1.60. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GRI is 3.00M, and currently, shorts hold a 1.81% of that float. The average trading volume for GRI on April 19, 2024 was 745.39K shares.
GRI’s Market Performance
The stock of GRI Bio Inc (GRI) has seen a 3.58% increase in the past week, with a -33.56% drop in the past month, and a -72.22% fall in the past quarter. The volatility ratio for the week is 5.59%, and the volatility levels for the past 30 days are at 8.70% for GRI. The simple moving average for the last 20 days is -13.63% for GRI stock, with a simple moving average of -93.55% for the last 200 days.
GRI Trading at -33.69% from the 50-Day Moving Average
After a stumble in the market that brought GRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.54% of loss for the given period.
Volatility was left at 8.70%, however, over the last 30 days, the volatility rate increased by 5.59%, as shares sank -28.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.33% lower at present.
During the last 5 trading sessions, GRI rose by +9.67%, which changed the moving average for the period of 200-days by -98.25% in comparison to the 20-day moving average, which settled at $0.6010. In addition, GRI Bio Inc saw -80.37% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GRI
Current profitability levels for the company are sitting at:
- -2.36 for the present operating margin
- 1.0 for the gross margin
The net margin for GRI Bio Inc stands at -2.47. The total capital return value is set at -49.22. Equity return is now at value -1021.38, with -373.75 for asset returns.
Based on GRI Bio Inc (GRI), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -642.14. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -12.99.
Currently, EBITDA for the company is -11.33 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of -0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.09.
Conclusion
In conclusion, GRI Bio Inc (GRI) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
